CytomX surges on positive data for ‘masked’ ADC in colorectal cancer
admin CytomX Therapeutics, a biopharmaceutical company focused on developing novel cancer therapies, announced on March 16,...
fda
FDA Revolutionizes Product Safety Monitoring with Unified Surveillance Dashboard, Consolidating Disparate Systems for Enhanced Utility and Efficiency
The U.S. Food and Drug Administration (FDA) has announced a significant overhaul of its product...
Eli Lilly Urges FDA to Recall Compounded Zepbound, Citing "Dangerous" Impurities and "Unknown Risks" in Unauthorized Formulations
Eli Lilly has intensified its campaign against compounded versions of its blockbuster obesity drug Zepbound...
FDA Streamlines Biosimilar Approval Pathway to Boost Competition and Lower Drug Costs
The U.S. Food and Drug Administration (FDA) has announced significant draft guidance aimed at accelerating...
Biopharma Sector Navigates Layoffs, Regulatory Hurdles, and Clinical Breakthroughs as Companies Adapt to Evolving Market Dynamics
The biopharmaceutical landscape is currently characterized by a complex interplay of strategic restructurings, significant workforce...
GSK’s Arexvy Secures Expanded FDA Approval for Younger Adults with High-Risk Conditions, Marking a Pivotal Win in a Challenging Regulatory Landscape
The U.S. Food and Drug Administration (FDA) has granted an expanded approval for GSK’s respiratory...
FDA Clears First-of-Its-Kind Allogeneic Stem Cell Therapy for Epilepsy Human Trials, Signifying a Global Biotech Shift
The U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance for...
BioNTech Founders Ugur Sahin and Özlem Türeci to Depart, Launching New mRNA Discovery Venture
Ugur Sahin and Özlem Türeci, the visionary co-founders who meticulously steered BioNTech from a nascent...
Biopharma Sector Buzzes with Strategic Approvals, Key Partnerships, and Market Reactions Across Global Health Landscapes
The biopharmaceutical industry is currently a hotbed of activity, marked by significant regulatory milestones, innovative...
Roche’s Amylin-Targeting Obesity Drug Petrelintide Underperforms in Phase 2, Raising Questions on Market Competitiveness
Basel, Switzerland – Hopes for Roche’s amylin-targeting obesity drug, petrelintide, have been tempered following the...